| # | Title | Journal | Year | Citations |
|---|
| 1 | The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro | Antiviral Research | 2020 | 1,567 |
| 2 | The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade | Antiviral Research | 2020 | 1,450 |
| 3 | Present and future arboviral threats | Antiviral Research | 2010 | 1,162 |
| 4 | Favipiravir (T-705), a novel viral RNA polymerase inhibitor | Antiviral Research | 2013 | 840 |
| 5 | Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro | Antiviral Research | 2020 | 737 |
| 6 | The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds | Antiviral Research | 2015 | 680 |
| 7 | Coronavirus membrane fusion mechanism offers a potential target for antiviral development | Antiviral Research | 2020 | 635 |
| 8 | Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity | Antiviral Research | 2013 | 613 |
| 9 | Crimean?Congo hemorrhagic fever | Antiviral Research | 2004 | 582 |
| 10 | Zika virus: History, emergence, biology, and prospects for control | Antiviral Research | 2016 | 571 |
| 11 | Antiviral effect of catechins in green tea on influenza virus | Antiviral Research | 2005 | 550 |
| 12 | A three-dimensional model to analyze drug-drug interactions | Antiviral Research | 1990 | 543 |
| 13 | Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein | Antiviral Research | 2018 | 542 |
| 14 | Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines | Antiviral Research | 1987 | 518 |
| 15 | Protease inhibitors targeting coronavirus and filovirus entry | Antiviral Research | 2015 | 513 |
| 16 | Tick-borne encephalitis | Antiviral Research | 2003 | 494 |
| 17 | Identification of natural compounds with antiviral activities against SARS-associated coronavirus | Antiviral Research | 2005 | 474 |
| 18 | Of chloroquine and COVID-19 | Antiviral Research | 2020 | 468 |
| 19 | The SARS coronavirus nucleocapsid protein – Forms and functions | Antiviral Research | 2014 | 436 |
| 20 | Herpes simplex encephalitis: Adolescents and adults | Antiviral Research | 2006 | 434 |
| 21 | Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds | Antiviral Research | 2005 | 430 |
| 22 | Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model | Antiviral Research | 2014 | 428 |
| 23 | The flavivirus NS1 protein: Molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker | Antiviral Research | 2013 | 425 |
| 24 | Type 1 interferons as a potential treatment against COVID-19 | Antiviral Research | 2020 | 425 |
| 25 | Crimean–Congo hemorrhagic fever | Antiviral Research | 2004 | 416 |
| 26 | Nitazoxanide: A first-in-class broad-spectrum antiviral agent | Antiviral Research | 2014 | 415 |
| 27 | Antiviral drugs for cytomegalovirus diseases | Antiviral Research | 2006 | 407 |
| 28 | Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction | Antiviral Research | 2007 | 400 |
| 29 | Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase | Antiviral Research | 2019 | 398 |
| 30 | T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections | Antiviral Research | 2009 | 393 |
| 31 | Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy | Antiviral Research | 2013 | 388 |
| 32 | The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic | Antiviral Research | 2010 | 386 |
| 33 | Antiviral activities of lactoferrin | Antiviral Research | 2001 | 383 |
| 34 | Arbidol as a broad-spectrum antiviral: An update | Antiviral Research | 2014 | 375 |
| 35 | Antiviral activities of type I interferons to SARS-CoV-2 infection | Antiviral Research | 2020 | 374 |
| 36 | Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research | Antiviral Research | 2013 | 354 |
| 37 | The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold | Antiviral Research | 2018 | 352 |
| 38 | The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1 | Antiviral Research | 1998 | 350 |
| 39 | The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo | Antiviral Research | 2002 | 348 |
| 40 | Inhibition of the infectivity of influenza virus by tea polyphenols | Antiviral Research | 1993 | 341 |
| 41 | Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS | Antiviral Research | 2014 | 340 |
| 42 | Accessory proteins of SARS-CoV and other coronaviruses | Antiviral Research | 2014 | 339 |
| 43 | Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009) | Antiviral Research | 2010 | 334 |
| 44 | Chikungunya: Evolutionary history and recent epidemic spread | Antiviral Research | 2015 | 331 |
| 45 | Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro | Antiviral Research | 1987 | 326 |
| 46 | Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro | Antiviral Research | 2009 | 326 |
| 47 | Resistance of influenza viruses to neuraminidase inhibitors — a review | Antiviral Research | 2000 | 316 |
| 48 | Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine | Antiviral Research | 2010 | 314 |
| 49 | T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV | Antiviral Research | 2017 | 314 |
| 50 | African swine fever | Antiviral Research | 2019 | 313 |
